Summary & Overview
HCPCS Q4342: Theramend, Per Square Centimeter
HCPCS Level II code Q4342 designates Theramend billed per square centimeter as an add-on reported in addition to a primary procedure. It captures use of a topical dermal or biologic product applied and billed by area, which matters nationally as payers and providers reconcile product-based add-on charges with procedure reimbursement. Accurate reporting of this code affects claim adjudication, product utilization tracking, and payment consistency across outpatient and clinic procedural settings.
Key payers covered in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for use of Theramend, common billing practices for add-on per-area products, and the elements typically examined in payer coverage and reimbursement policies. The publication highlights expected benchmarks and policy considerations relevant to national billing and coding operations, including how add-on area-based codes are handled relative to primary procedures.
This summary is intended to inform billing managers, compliance professionals, and policy analysts about the purpose of Q4342, typical settings where it is used, and the types of payer policies and benchmarks to review when validating claims and preparing documentation. Data not available in the input will be noted for those seeking deeper payer-specific coverage and coding guidance.
Billing Code Overview
HCPCS Level II code Q4342 represents Theramend billed per square centimeter as an add-on, list separately in addition to primary procedure. This code is used to report the Theramend product on a per-area basis when it is applied in conjunction with a primary procedure.
Service type: Topical biologic/dermal product application billed by area
Typical site of service: Outpatient procedural settings or clinic-based procedure areas
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a chronic, non-healing lower-extremity wound following a diabetic foot ulcer is evaluated in a wound care clinic. After conservative care including debridement, off-loading, infection control, and advanced dressings, the wound demonstrates a persistent full-thickness defect with stalled healing. The wound care team elects to apply a topical biologic scaffold product (Theramend) as an adjunctive therapy to promote granulation and re-epithelialization. The procedure is performed in an outpatient wound clinic or ambulatory surgery center. Workflow steps include wound assessment and measurement, wound bed preparation and debridement as indicated, cleansing and hemostasis, trimming/applying the Theramend material sized to the wound area (billed per square centimeter with Q4342 as an add-on), securement with appropriate dressing, patient and caregiver education on off-loading and dressing care, and scheduled follow-up for reassessment and potential repeat applications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Used when no special circumstances or modifiers apply to the service. |
22 |